Cargando…
Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond
Historically, aspirin has been the primary treatment for the prevention of ischaemic events in patients with coronary artery disease. For patients undergoing percutaneous coronary intervention (PCI) standard treatment has been 12 months of dual antiplatelet therapy (DAPT) with aspirin and clopidogre...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566303/ https://www.ncbi.nlm.nih.gov/pubmed/33930107 http://dx.doi.org/10.1093/ehjcvp/pvab035 |
_version_ | 1784593983601639424 |
---|---|
author | Wang, Rutao Wu, Sijing Gamal, Amr Gao, Chao Hara, Hironori Kawashima, Hideyuki Ono, Masafumi van Geuns, Robert-Jan Vranckx, Pascal Windecker, Stephan Onuma, Yoshinobu Serruys, Patrick W Garg, Scot |
author_facet | Wang, Rutao Wu, Sijing Gamal, Amr Gao, Chao Hara, Hironori Kawashima, Hideyuki Ono, Masafumi van Geuns, Robert-Jan Vranckx, Pascal Windecker, Stephan Onuma, Yoshinobu Serruys, Patrick W Garg, Scot |
author_sort | Wang, Rutao |
collection | PubMed |
description | Historically, aspirin has been the primary treatment for the prevention of ischaemic events in patients with coronary artery disease. For patients undergoing percutaneous coronary intervention (PCI) standard treatment has been 12 months of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, followed by aspirin monotherapy; however, DAPT is undeniably associated with an increased risk of bleeding. For over a decade novel P2Y(12) inhibitors, which have increased specificity, potency, and efficacy have been available, prompting studies which have tested whether these newer agents can be used in aspirin-free antiplatelet regimens to augment clinical benefits in patients post-PCI. Among these studies, the GLOBAL LEADERS trial is the largest by cohort size, and so far has provided a wealth of evidence in a variety of clinical settings and patient groups. This article summarizes the state-of-the-art evidence obtained from the GLOBAL LEADERS and other trials of aspirin-free strategies. |
format | Online Article Text |
id | pubmed-8566303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-85663032021-11-04 Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond Wang, Rutao Wu, Sijing Gamal, Amr Gao, Chao Hara, Hironori Kawashima, Hideyuki Ono, Masafumi van Geuns, Robert-Jan Vranckx, Pascal Windecker, Stephan Onuma, Yoshinobu Serruys, Patrick W Garg, Scot Eur Heart J Cardiovasc Pharmacother Review Historically, aspirin has been the primary treatment for the prevention of ischaemic events in patients with coronary artery disease. For patients undergoing percutaneous coronary intervention (PCI) standard treatment has been 12 months of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, followed by aspirin monotherapy; however, DAPT is undeniably associated with an increased risk of bleeding. For over a decade novel P2Y(12) inhibitors, which have increased specificity, potency, and efficacy have been available, prompting studies which have tested whether these newer agents can be used in aspirin-free antiplatelet regimens to augment clinical benefits in patients post-PCI. Among these studies, the GLOBAL LEADERS trial is the largest by cohort size, and so far has provided a wealth of evidence in a variety of clinical settings and patient groups. This article summarizes the state-of-the-art evidence obtained from the GLOBAL LEADERS and other trials of aspirin-free strategies. Oxford University Press 2021-04-30 /pmc/articles/PMC8566303/ /pubmed/33930107 http://dx.doi.org/10.1093/ehjcvp/pvab035 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Review Wang, Rutao Wu, Sijing Gamal, Amr Gao, Chao Hara, Hironori Kawashima, Hideyuki Ono, Masafumi van Geuns, Robert-Jan Vranckx, Pascal Windecker, Stephan Onuma, Yoshinobu Serruys, Patrick W Garg, Scot Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond |
title | Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond |
title_full | Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond |
title_fullStr | Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond |
title_full_unstemmed | Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond |
title_short | Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond |
title_sort | aspirin-free antiplatelet regimens after pci: insights from the global leaders trial and beyond |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566303/ https://www.ncbi.nlm.nih.gov/pubmed/33930107 http://dx.doi.org/10.1093/ehjcvp/pvab035 |
work_keys_str_mv | AT wangrutao aspirinfreeantiplateletregimensafterpciinsightsfromthegloballeaderstrialandbeyond AT wusijing aspirinfreeantiplateletregimensafterpciinsightsfromthegloballeaderstrialandbeyond AT gamalamr aspirinfreeantiplateletregimensafterpciinsightsfromthegloballeaderstrialandbeyond AT gaochao aspirinfreeantiplateletregimensafterpciinsightsfromthegloballeaderstrialandbeyond AT harahironori aspirinfreeantiplateletregimensafterpciinsightsfromthegloballeaderstrialandbeyond AT kawashimahideyuki aspirinfreeantiplateletregimensafterpciinsightsfromthegloballeaderstrialandbeyond AT onomasafumi aspirinfreeantiplateletregimensafterpciinsightsfromthegloballeaderstrialandbeyond AT vangeunsrobertjan aspirinfreeantiplateletregimensafterpciinsightsfromthegloballeaderstrialandbeyond AT vranckxpascal aspirinfreeantiplateletregimensafterpciinsightsfromthegloballeaderstrialandbeyond AT windeckerstephan aspirinfreeantiplateletregimensafterpciinsightsfromthegloballeaderstrialandbeyond AT onumayoshinobu aspirinfreeantiplateletregimensafterpciinsightsfromthegloballeaderstrialandbeyond AT serruyspatrickw aspirinfreeantiplateletregimensafterpciinsightsfromthegloballeaderstrialandbeyond AT gargscot aspirinfreeantiplateletregimensafterpciinsightsfromthegloballeaderstrialandbeyond |